{
    "analysis_session": {
        "id": "session_20250218_002",
        "timestamp": "2025-02-18T15:09:32+08:00"
    },
    "final_result_id": "fr_20250218_002",
    "evidence_chain": {
        "entity_recognition_id": "er_20250218_002",
        "indication_analysis_id": "ia_20250218_002",
        "analysis_id": "a_20250218_002"
    },
    "final_judgment": {
        "category": "合理超说明书用药",
        "confidence": 0.85,
        "explanation": "虽然超出药品说明书范围，但有充分的临床证据支持在特发性肺纤维化合并肺动脉高压患者中使用",
        "recommendation": "建议用药，但需要：\n1. 密切监测疗效和不良反应\n2. 定期评估获益风险比\n3. 加强随访，关注长期安全性"
    },
    "summary": {
        "indication_match": {
            "result": "部分匹配",
            "confidence": 0.85,
            "notes": "匹配继发疾病(PAH)但未覆盖原发病(IPF)"
        },
        "similarity_score": 0.825,
        "evidence_strength": 0.85,
        "benefit_risk_ratio": 0.75
    },
    "monitoring_plan": {
        "efficacy_indicators": [
            "肺动脉压力",
            "6分钟步行距离",
            "呼吸困难评分",
            "生活质量评分"
        ],
        "safety_monitoring": [
            "肝肾功能",
            "血压",
            "不良反应观察"
        ],
        "follow_up_schedule": "首月每周随访一次，后续每月随访一次",
        "adjustment_criteria": {
            "dose_reduction": [
                "出现严重不良反应",
                "肝功能异常"
            ],
            "discontinuation": [
                "原发病明显进展",
                "不能耐受的不良反应",
                "无明显临床获益"
            ]
        }
    }
}
